Home » Newsletters » BioWorld Asia

BioWorld Asia

May 19, 1999

View Archived Issues

Peptides Oravax Buyout Completed: $20M Deal

VEGF Research Zeroes In On Varied Protein Types For Angiogenesis Clues

Cyclacel Financing Gets #5.3M For Cancer Work

KuDOS Raises #5M, Hires Ward As CEO

Australia Spending A$17.5M For Biotech Rules Agency

GPC, HMR Deal Aims At Antifungal Targets

Enzyme Prodrug Company In Vector Deal With Vion

Centocor Seeking Stock For Trinitys Default

Nexias Cloned Goats Aid Spider-Silk Effort

Medullary Breast Cancer Gene Clue Discovered

DrugAbuse Sciences Starts Naltrexon Trials

CAT Results Suggest Eye-Drug Applications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy
BioWorld
Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...